Senior Advisor with a focus on Life Sciences and Diagnostics.

Engaged by Proteomics International, Perth Australia. Proteomics International has developed a proprietary Mass Spec biomarker discovery platform. PI has recently discovered biomarkers for the diagnosis of Diabetic Kidney disease and has further developed and validated a multiplex ELISA assay for these markers. Proteomics International is seeking partners to further develop the assay for CDx, IVD and CLIA LTD applications. PI is also seeking new collaboration partners for their biomarker discovery services utilizing their proprietary platform in their ISO 17025 certified laboratory. Please contact me for further information.Consulting services specializing in acquisitions and mergers, partnerships, collaborations, in and out licensing of Intellectual Property, and business strategy development.36 years of Life science, Biotechnology and Diagnostic business experience includes 13 years of Corporate Business Development.Specialties: *Project Management *Team Building *Commercialization *Business Development *Strategic Management *Acquisitions *Partnerships and Alliances *Licensing *Genomics *Diagnostics

Head of Business Development with a focus on the commercialization/licensing of our PromarkerD assay for diabetic kidney disease.

Key member of the deal team leading to a successful exit; acquisition by Meridian Bioscience.

Drives deal transactions and oversees growth opportunities while spearheading acquisitions, licensing, partnerships and business collaborations.­ Executed and enhanced profitability of business deals by developing positive relationships with company founders and clearly assessing and communicating value proposition while championing best practices for partnerships and acquisitions: - Accessed sales channels, research and development (R&D) resources, emerging markets and competitive threats. - Fostered smooth integration of acquired companies into PerkinElmer family. - Minimized disruptions of sales momentum, R&D pipeline progress and profitability stream.­ Recognized as key contributor for effectively closing 10 acquisitions: - Champions successful closings by accurately negotiating valuation and key terms while managing cross-functional due diligence, internal processes and communications.- Advanced company growth with recentl acquisitions, including: ID Biologicals, Signature Genomics, Symbio Diagnostics (China), acquisition and collaboration with Mediscan (India).­ Commended for maintaining objectivity while directing due diligence initiatives, including recommendation to "pass" on clinical pathology lab, saving $60M on acquisition expenses that would have been a poor investment. - Discovered through due diligence investigation about critical reimbursement risk on valuation that prompted PerkinElmer to accept recommendation for not moving forward with deal. - Proved prudent as wise council when reimbursement levels were cut by 50% just 2 weeks after decision to pass on deal. - Saved company additional due diligence expenses and possibility for dilutive acquisition by effectively assessing merits of deal accurately early on.

Spearheaded acquisitions, managing out- and in-licensing, developing partnerships / collaborations, and scouting for potential new acquisitions.­ Led due diligence efforts for several prospective acquisitions in 2005, ensuring cross-functional buy-in, which reduced corporate exposure and vetted growth opportunities. - Resulted in successful acquisitions during 2006, enabling PerkinElmer to build new franchises in Proteomics and DNA microarrays for life science research.­ Closed out-licensing deals successfully with Abbott, Invitrogen, Ventana Medical Systems, Roche Pharmaceuticals, GmbH, and Molecular Probes by using effective business, communications, and project management competencies.­ Credited for closing in-licensing deals with Luminex, Diagnostic technologies (Israel), KREATECH Biotechnology of Netherlands, Affymetrix, Molecular Probes, Jacobi Medical Center, and King’s College London by: - Negotiating mutually beneficial arrangements based on understanding key needs for both parties and skillfully building

Managed team ERP implementation project of 10 full-time employees, 15 part-time staff, and 10 consultants with a total budget of $10M.­ Increased organizational efficiency and provided common platform for latest software with smooth implementation of Oracle / GEMMS application package in US and Europe without service disruptions.­ Managed requirement gathering, business process redesign for finance, sales and marketing, order fulfillment, manufacturing, and supply chain modules by: - Achieving "go live" date within budget and 2 months ahead of schedule for both US and Europe.

Oversaw critical business functions needed for timely shipment of radioactive materials with short half-lives. Supervised 25 employees at Boston site shipping and dock operations that handled average of 5500 packages shipped per week on dry ice / blue ice / ambient.­ Ensured timely inventory management by meeting production schedules and maintaining optimal inventory levels, fostering profitability through effective staff supervision and resource allocation: - Used best practices in running materials planning group consisting of master scheduler, 3 planners, and 1 buy item planner and operating BRP / MRP II system utilizing AMAPS software.